Brazil's role in the global vaccination race is under significant scrutiny, particularly as it lacks its own developed vaccines for widespread use. Despite being a model of distribution and access to immunizations, the country has not achieved self-sufficiency in vaccine production, a critical area that is increasingly technological and dominated by a handful of nations. Epidemiologist Carla Domingues, who oversaw the National Immunization Program (PNI), points out that Brazil has not participated in the vaccine race as it lacks a domestically developed vaccine that has reached the public.

Esper Kallas, the director of Instituto Butantan, provides a slightly more optimistic perspective. He acknowledges that Brazil does have a presence in the global vaccination context, citing that Butantan ranks among the top ten producers of influenza vaccines worldwide. However, he also recognizes the challenges that the domestic immunobiological industry faces in keeping up with advancements and competition from other nations.

The insights provided by both Domingues and Kallas reflect a broader concern regarding Brazil's preparedness for future public health challenges. The country's reliance on imported vaccines, despite its strengths in distribution, raises questions about its independence and ability to respond swiftly to health emergencies. For Brazil to secure a more prominent position in the vaccine sector, strategic investments in research and development are essential, as well as fostering innovation within its pharmaceutical landscape.